In theory, checkpoint inhibition therapy may be an attractive option in a subset of SLE patients with diminished CD8+ T cell function [102] as boosting defective CD8+ T cell responses could enhance infection protection and cancer immunosurveillance in these patients. Here, CD8A is linked to systemic lupus erythematosus.